Skip to main content

Advertisement

SpringerLink
Log in

Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor

  • Short Communication
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Imatinib is a tyrosine kinase inhibitor with activity in gastrointestinal stromal tumor and a variety of other solid and hematological malignancies. Studies in vitro and in a mouse model suggested that the imatinib might also be active in malignant Leydig cell tumor. We report on the—to our knowledge—first treatment experiment with imatinib in a patient with metastatic Leydig cell tumor. Unfortunately, the tumor progressed during treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Basciani S, Brama M, Mariani S, De Luca G, Arizzi M, Vesci L, Pisano C, Dolci S, Spera G, Gnessi L (2005) Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity. Cancer Res 65:1897–1903

    Article  PubMed  CAS  Google Scholar 

  2. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, Martens M, van den Borneb B, Cole P, Sciot R, Dumez H, Silberman S, Mortelmans L, van Oosteromb A (2003) 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®). Eur J Cancer 39:2012–2020

    Article  PubMed  CAS  Google Scholar 

  3. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052–1056

    Article  PubMed  CAS  Google Scholar 

  4. Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172–187

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University Hospital, Technical University of Dresden, Fetscherstrasse 74, 01307, Dresden, Germany

    Michael Froehner & Manfred P. Wirth

  2. Department of Nuclear Medicine and PET Center Rossendorf, University Hospital, Technical University of Dresden, Fetscherstrasse 74, 01307, Dresden, Germany

    Bettina Beuthien-Baumann

  3. Department of Pathology, University Hospital, Technical University of Dresden, Fetscherstrasse 74, 01307, Dresden, Germany

    Dag-Daniel Dittert

  4. Department of Medical Oncology, University Hospital, Technical University of Dresden, Fetscherstrasse 74, 01307, Dresden, Germany

    Ulrich Schuler

Authors
  1. Michael Froehner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bettina Beuthien-Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dag-Daniel Dittert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ulrich Schuler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Manfred P. Wirth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Froehner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Froehner, M., Beuthien-Baumann, B., Dittert, DD. et al. Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor. Cancer Chemother Pharmacol 58, 716–718 (2006). https://doi.org/10.1007/s00280-005-0181-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-005-0181-6

Keywords

Search

Navigation